420 related articles for article (PubMed ID: 11583303)
1. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
2. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
Stewart D; Kong M; Novokhatny V; Jesmok G; Marder VJ
Blood; 2003 Apr; 101(8):3002-7. PubMed ID: 12446443
[TBL] [Abstract][Full Text] [Related]
3. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
4. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
6. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
Landskroner K; Olson N; Jesmok G
J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
Montoney M; Gardell SJ; Marder VJ
Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
10. Revival of plasmin as a therapeutic agent?
Collen D
Thromb Haemost; 2001 Sep; 86(3):731-2. PubMed ID: 11583301
[No Abstract] [Full Text] [Related]
11. Structure and activity of plasmin and other direct thrombolytic agents.
Novokhatny V
Thromb Res; 2008; 122 Suppl 3():S3-8. PubMed ID: 18718639
[TBL] [Abstract][Full Text] [Related]
12. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
Dupe RJ; English PD; Smith RA; Green J
Thromb Haemost; 1981 Aug; 46(2):528-34. PubMed ID: 6458112
[TBL] [Abstract][Full Text] [Related]
15. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
16. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
17. [Staphylokinase--a specific plasminogen activator].
Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
[TBL] [Abstract][Full Text] [Related]
18. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of the fibrinolytic system in the newborn].
Schlegel N; Hurtaud-Roux MF; Beaufils F
Ann Pediatr (Paris); 1993 Feb; 40(2):70-4. PubMed ID: 8457135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
